Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.

Abstract: A polar transmitter including a digital power amplifier cell that includes a first circuit and an amplifier circuit. The first circuit is configured to receive a phase modulated carrier signal and to generate a PMOS control signal and an NMOS control signal such that the PMOS control signal and the NMOS control signal have different duty cycles. The amplifier circuit is configured to receive the PMOS control signal at a PMOS transistor and the NMOS control signal at an NMOS transistor. The first circuit is configured to align the PMOS control signal and the NMOS control signal with respect to one another such that a time that the NMOS transistor and the PMOS transistor of the amplifier circuit are simultaneously conducting is minimized. The amplifier circuit is configured to generate an amplified modulated carrier signal in response to the PMOS and NMOS control signals.

Abstract: Disclosed are compounds of Formula (I?) methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

Abstract: Embodiments of the present disclosure provide for methods of making quantum dots (QDs) (passivated or unpassivated) using a continuous flow process, systems for making QDs using a continuous flow process, and the like. In one or more embodiments, the QDs produced using embodiments of the present disclosure can be used in solar photovoltaic cells, bio-imaging, IR emitters, or LEDs.

Abstract: In an embodiment, a processor includes multiple processing engines and a power control unit. The power control unit is to: maintain a first utilization metric for a first processing engine; detect a thread transfer from a first processing engine to a second processing engine; and generate, using the first utilization metric for the first processing engine, a second utilization metric for a second processing engine. Other embodiments are described and claimed.

Abstract: The present disclosure relates to heterocyclic compounds, and pharmaceutical compositions of the same, that are modulators/inhibitors of HDACs, such as HDAC8 and are useful in the treatment of HDAC-associated diseases.

Abstract: In an embodiment, a processor for performance state adjustment includes a plurality of processing engines (PEs), a power control unit, and an input/output memory management unit (IOMMU). The IOMMU is to determine a destination PE for a user interrupt based on mapping data of the IOMMU, and to send a notification of the user interrupt to the power control unit. The notification indicates the destination PE for the user interrupt. The power control unit is to adjust a performance state of the destination PE in response to the notification of the user interrupt. Other embodiments are described and claimed.

Abstract: A polar transmitter including a digital power amplifier cell that includes a first circuit and an amplifier circuit. The first circuit is configured to receive a phase modulated carrier signal and to generate a PMOS control signal and an NMOS control signal such that the PMOS control signal and the NMOS control signal have different duty cycles. The amplifier circuit is configured to receive the PMOS control signal at a PMOS transistor and the NMOS control signal at an NMOS transistor. The first circuit is configured to align the PMOS control signal and the NMOS control signal with respect to one another such that a time that the NMOS transistor and the PMOS transistor of the amplifier circuit are simultaneously conducting is minimized. The amplifier circuit is configured to generate an amplified modulated carrier signal in response to the PMOS and NMOS control signals.

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.

Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. Also provided are methods of using the compounds of Formula (I) for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.

Abstract: In an embodiment, a processor for performance state adjustment includes a plurality of processing engines (PEs), a power control unit, and an input/output memory management unit (IOMMU). The IOMMU is to determine a destination PE for a user interrupt based on mapping data of the IOMMU, and to send a notification of the user interrupt to the power control unit. The notification indicates the destination PE for the user interrupt. The power control unit is to adjust a performance state of the destination PE in response to the notification of the user interrupt. Other embodiments are described and claimed.

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

Abstract: The invention concerns to a gradient coil assembly (62) for use in a Magnetic Resonance Imaging (MRI) system. The gradient coil assembly (62) comprises primary coils (68), shield coils (72) and a supporting structure (10) being arranged between the primary coils (68) and the shield coils (72), wherein the supporting structure (10) comprises at least a supporting element (12) comprising a first end face (14) and at least a first recess (24) with an opening (26) in the first end face (14), wherein the first recess (24) extends in a longitudinal direction (18) of the supporting element (12) forming a tray for receiving a passive shim bar.

Abstract: The invention relates to cooling a gradient coil (3) of a magnetic resonance imaging system (11). It is an object of the invention to provide an improved assembly of a magnetic resonance imaging apparatus with a gradient coil (3) which allows a cooling of the gradient coil (3) in such a way that a better homogeneity of the temperature distribution an reduced hot spots effects can be achieved.

Abstract: A method and apparatus for providing recommended contents. The method comprises: A search query being received; an event being selected from a predetermined event set based on the search query; the recommended contents being provided in a structured template including one or more elements; each element is associated with a feature of the event; each feature of the event corresponds to a search intent. Each element includes one or more sub-contents, and each sub-content is correlated to corresponding recommended contents.

Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

Abstract: Disclosed are compounds of Formula (I?) methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.